Feng Lin

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Ejection Fraction

Epidermal Growth Factor Receptor

Metastatic Breast Cancer

Top Venues

Journal of comparative effectiveness research

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews

Drugs - real world outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Clara Lam, Brandon J Diessner, Katherine Andrade, Sydnie Stackland, Leah Park, Sandhya Mehta, Feng Lin, Winghan Jackie Kwong
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of comparative effectiveness research (2024)
Clara Lam, Brandon J Diessner, Katherine Andrade, Sydnie Stackland, Leah Park, Sandhya Mehta, Feng Lin, Winghan Jackie Kwong
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of comparative effectiveness research (2024)
Clara Lam, Brandon J Diessner, Katherine Andrade, Sydnie Stackland, Leah Park, Sandhya Mehta, Feng Lin, Winghan Jackie Kwong
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of comparative effectiveness research (2024)
Feng Lin, Kathleen Wilson, Winghan J Kwong, John A Abraham
Understanding the Effect of Osteoarthritis on Surgical Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients With Tenosynovial Giant Cell Tumors. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews 7 (5) (2023)
Afsaneh Barzi, Feng Lin, Jinlin Song, Clara Lam, Xiaoyu Nie, Ahmed Noman, Winghan J Kwong
Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA. Drugs - real world outcomes (2023)
Feng Lin, Winghan Jacqueline Kwong, Irene Pan, Xin Ye, Dong Dai, William Tap
Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor. The oncologist (2023)